File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Defining an optimal surgical strategy for treatment of recurrent hepatocellular carcinoma after hepatectomy: re-resection or radiofrequency ablation?

TitleDefining an optimal surgical strategy for treatment of recurrent hepatocellular carcinoma after hepatectomy: re-resection or radiofrequency ablation?
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2011
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 473, abstract PP36-07 How to Cite?
AbstractBACKGROUND: Tumor recurrence after resection of hepatocellular carcinoma (HCC) is a common phenomenon with a 5-year recurrence rate over 50%. Aggressive salvage treatment policy in the form of re-resection or radiofrequency ablation (RFA) improves the prognosis of patients with recurrent disease. However, the choice of treatment to achieve better survival benefit in the management of recurrent HCC is not yet clear. METHODS: From January 2001 to December 2008, 179 patients developed intrahepatic recurrences after hepatectomy for HCC in our center. 29 patients received re-resections and 45 patients received RFA as salvage treatment. Patient characteristics, clinicopathological data, and survival outcomes were reviewed, and compared between the two groups. P value < 0.05 was considered to be significant. Results: Patients in the RFA group were older than those in the re-resection group (59 vs. 52-year-old). Nonetheless, the liver function status, staging of the initial tumor and time to develop first recurrence after hepatectomy for initial tumor (12.2 vs. 8.7 months, p = 0.84) were comparable between the two groups. There was no difference in recurrent tumor size (2.1 vs. 2.1 cm, p = 0.73) and tumor multi-focality. The time to develop further tumor recurrence after re-resection and RFA were 5.9 and 4.0 months (p = 0.30). The 1-, 3- and 5-year tumor-free survival rates after re-resection were 41.4, 24.2 and 24.2%, respectively, and after RFA were 32.2, 12.4 and 9.3% respectively (P = 0.14). The 1-, 3-, and 5-year overall survival rates after re-resection were 89.7, 56.5 and 35.2%, respectively, and after RFA were 83.7, 43.1 and 29.1%, respectively (P = 0.48). The 1-, 3- and 5-year overall survival rates after hepatectomy for initial tumor in the re-resection group were 89.7, 82.3 and 55.7%, and in the RFA group were 95.6, 68.2 and 44.5%, respectively. CONCLUSION: Both RFA and re-resection attain similar survival benefit in the management of recurrent HCC after hepatectomy.
Descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
Persistent Identifierhttp://hdl.handle.net/10722/136098
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, Aen_US
dc.contributor.authorPoon, Ren_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorLo, CMen_US
dc.contributor.authorFan, STen_US
dc.date.accessioned2011-07-27T02:02:47Z-
dc.date.available2011-07-27T02:02:47Z-
dc.date.issued2011en_US
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 473, abstract PP36-07en_US
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/136098-
dc.descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011-
dc.description.abstractBACKGROUND: Tumor recurrence after resection of hepatocellular carcinoma (HCC) is a common phenomenon with a 5-year recurrence rate over 50%. Aggressive salvage treatment policy in the form of re-resection or radiofrequency ablation (RFA) improves the prognosis of patients with recurrent disease. However, the choice of treatment to achieve better survival benefit in the management of recurrent HCC is not yet clear. METHODS: From January 2001 to December 2008, 179 patients developed intrahepatic recurrences after hepatectomy for HCC in our center. 29 patients received re-resections and 45 patients received RFA as salvage treatment. Patient characteristics, clinicopathological data, and survival outcomes were reviewed, and compared between the two groups. P value < 0.05 was considered to be significant. Results: Patients in the RFA group were older than those in the re-resection group (59 vs. 52-year-old). Nonetheless, the liver function status, staging of the initial tumor and time to develop first recurrence after hepatectomy for initial tumor (12.2 vs. 8.7 months, p = 0.84) were comparable between the two groups. There was no difference in recurrent tumor size (2.1 vs. 2.1 cm, p = 0.73) and tumor multi-focality. The time to develop further tumor recurrence after re-resection and RFA were 5.9 and 4.0 months (p = 0.30). The 1-, 3- and 5-year tumor-free survival rates after re-resection were 41.4, 24.2 and 24.2%, respectively, and after RFA were 32.2, 12.4 and 9.3% respectively (P = 0.14). The 1-, 3-, and 5-year overall survival rates after re-resection were 89.7, 56.5 and 35.2%, respectively, and after RFA were 83.7, 43.1 and 29.1%, respectively (P = 0.48). The 1-, 3- and 5-year overall survival rates after hepatectomy for initial tumor in the re-resection group were 89.7, 82.3 and 55.7%, and in the RFA group were 95.6, 68.2 and 44.5%, respectively. CONCLUSION: Both RFA and re-resection attain similar survival benefit in the management of recurrent HCC after hepatectomy.-
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology Internationalen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleDefining an optimal surgical strategy for treatment of recurrent hepatocellular carcinoma after hepatectomy: re-resection or radiofrequency ablation?en_US
dc.typeConference_Paperen_US
dc.identifier.emailChan, A: acchan@hku.hken_US
dc.identifier.emailPoon, R: poontp@hku.hken_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.authorityChan, A=rp00310en_US
dc.identifier.authorityPoon, R=rp00446en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.doi10.1007/s12072-010-9241-z-
dc.identifier.hkuros188352en_US
dc.identifier.volume5en_US
dc.identifier.issue1-
dc.identifier.spage473en_US
dc.identifier.epage473en_US
dc.identifier.isiWOS:000300105300001-
dc.publisher.placeUnited States-
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 473, abstract PP36-07-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats